TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35568909

Group type: EXPERIMENTAL
Intervention: Precision cancer drugs through IMPRESS-Norway
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular diagnostics funded by the public health care system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted therapies
Number of subjects: 0
Study: 35569489

Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Number of subjects: 1047
Study: 35569802

Group type: EXPERIMENTAL
Intervention: gefapixant, a P2 × 3-receptor antagonist
Number of subjects: 2044
Study: 35570015

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.96% zinc (zinc oxide, zinc citrate) in a silica base (Test 1)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.454% SnF (Test 2)
Number of subjects: 83
Study: 35570249

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 0
Study: 35570253

Group type: EXPERIMENTAL
Intervention: Caffeine (CYP1A2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Efavirenz (CYP2B6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (CYP2C9)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Omeprazole (CYP2C19)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metoprolol (CYP2D6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metabolic ratio for paraxanthine/caffeine (CYP1A2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metabolic ratio for 8-hydroxyefavirenz/efavirenz (CYP2B6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metabolic ratio for 5-hydroxyomeprazole/omeprazole (CYP2C19)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metabolic ratio for α-hydroxymetoprolol/metoprolol (CYP2D6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metabolic ratio for 1'-hydroxymidazolam/midazolam (CYP3A)
Number of subjects: 36
Study: 35570280

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2-I)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Other oral anti-diabetic agents (non-SGLT2-I)
Number of subjects: 583
Study: 35570301

Group type: EXPERIMENTAL
Intervention: Therapist-oriented home rehabilitation (TOHR)
Number of subjects: 12
Study: 35570383

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg) combined with aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 35570651

Group type: EXPERIMENTAL
Intervention: Resting-State Functional Magnetic Resonance Imaging
Number of subjects: 0
Study: 35570723

Group type: EXPERIMENTAL
Intervention: Signs/symptoms of COVID-19 (fever, cough, dyspnea, atypical symptoms, delirium)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Tachypnea
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Low oxygen saturation
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 981
Study: 35570846

Group type: EXPERIMENTAL
Intervention: Plexin-B2 knockdown
Number of subjects: 0
Study: 35570983

Group type: EXPERIMENTAL
Intervention: VIS649 0.5 mg/kg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: VIS649 2.0 mg/kg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: VIS649 6.0 mg/kg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: VIS649 12.0 mg/kg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: VIS649 6.0 mg/kg + vaccine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo + vaccine
Number of subjects: 51
Study: 35570989

Group type: EXPERIMENTAL
Intervention: Dapagliflozin treatment
Number of subjects: 14
Study: 35571041

Group type: EXPERIMENTAL
Intervention: Standard Newborn Screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newborn Genomic Sequencing
Number of subjects: 0
Study: 35571196

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer drug-eluting stents (BP-DES)
Number of subjects: 127731

Group type: COMPARATOR
Intervention: Durable polymer drug-eluting stents (DP-DES)
Number of subjects: 127731
Study: 35571641

Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT followed by surgical resection
Number of subjects: 39
Study: 35571881

Group type: EXPERIMENTAL
Intervention: High Protein, Low Glycemic Index (HPLG) dietary intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Balanced diet control group
Number of subjects: 63
Study: 35571890

Group type: EXPERIMENTAL
Intervention: Liquid meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Solid meal
Number of subjects: 36
Study: 35571902

Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 35571928

Group type: EXPERIMENTAL
Intervention: IQP-AE-103 (proprietary combination of dehydrated okra powder and inulin)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 35571933

Group type: EXPERIMENTAL
Intervention: multi-nutrient fortified dairy-based drink
Number of subjects: 0
Study: 35572309

Group type: EXPERIMENTAL
Intervention: Inner Engineering Completion Online (IECO) intervention, which includes a 21-min meditation practice called Shambhavi Mahamudra Kriya.
Number of subjects: 68
Study: 35572519

Group type: EXPERIMENTAL
Intervention: Isocaloric Ketogenic Diet (75% fat, 20% protein, 5% carbohydrate) for 3 days
Number of subjects: 15
Study: 35572740

Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation (NI) at diluted concentrations of 0.4%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation (NI) at diluted concentrations of 0.5%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation (NI) at diluted concentrations of 0.6%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PVP-I nasal spray (NS) at diluted concentrations of 0.5%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PVP-I nasal spray (NS) at diluted concentrations of 0.6%
Number of subjects: 189

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 189
Study: 35572990

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 1399
Study: 35573002

Group type: EXPERIMENTAL
Intervention: Treatment for chronic-active antibody-mediated rejection (caABMR)
Number of subjects: 16
Study: 35573309

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 35573377

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smartphone and smartwatch sensor data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social media data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic health records (EHR) data
Number of subjects: 0
Study: 35574003

Group type: EXPERIMENTAL
Intervention: Basal insulin
Number of subjects: 393

Group type: COMPARATOR
Intervention: Premixed insulin
Number of subjects: 393
Study: 35574368

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NACT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy (NACRT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (NACT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (NACRT)
Number of subjects: 75
Study: 35574391

Group type: EXPERIMENTAL
Intervention: Concurrent scalp-sparing radiation (60 Gy in 30 fractions) with TMZ (75 mg/m²)
Number of subjects: 30
Study: 35574426

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily (b.d.)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (b.d.)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study: 35574491

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35574651

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35574956

Group type: EXPERIMENTAL
Intervention: Biomarker-enhanced CA-AKI model including osteopontin and cystatin C
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Kidney injury molecule-1 and interleukin-18
Number of subjects: 1114
Study: 35575302

Group type: EXPERIMENTAL
Intervention: Non-invasive measurement using near infrared spectroscopy (NIRS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Invasive measurement of oxygen delivery (DO2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Invasive measurement of oxygen consumption (VO2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Invasive measurement of oxygen extraction ratio (O2ER)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of SveO2 and NIRS
Number of subjects: 40
Study: 35575381

Group type: EXPERIMENTAL
Intervention: S predicted-progression score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P predicted-progression score
Number of subjects: 0
Study: 35575445

Group type: EXPERIMENTAL
Intervention: Turkish version of Smartphone Impact Scale (SIS-T)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Turkish version of Smartphone Addiction Scale (SAS-T)
Number of subjects: 264
Study: 35575702

Group type: EXPERIMENTAL
Intervention: Behavioral flexibility assessed via the Do Something Different Questionnaire
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Health behaviors assessed via HPLP-II at baseline, 3 months, and 6 months
Number of subjects: 387
Study: 35575974

Group type: EXPERIMENTAL
Intervention: DTaP-IPV vaccine (TETRAXIM™)
Number of subjects: 647
Study: 35576349

Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate with adjunct Misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35576384

Group type: EXPERIMENTAL
Intervention: Antibiotics (intravenous ertapenem followed by oral levofloxacin and metronidazole)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 35576502

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open abdominal surgery
Number of subjects: 0
Study: 35576508

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus nivolumab (paclitaxel 200 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus nivolumab
Number of subjects: 0
Study: 35576529

Group type: EXPERIMENTAL
Intervention: Mitapivat (AG-348) 50 mg BID
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mitapivat (AG-348)
Number of subjects: 16
Study: 35576565

Group type: EXPERIMENTAL
Intervention: Mobile app Malo
Number of subjects: 4000
Study: 35576566

Group type: EXPERIMENTAL
Intervention: Micodigest 2.0
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 35576569

Group type: EXPERIMENTAL
Intervention: Step Away app
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Step Away chatbot
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 150
Study: 35576573

Group type: EXPERIMENTAL
Intervention: i♥rhythm intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 40
Study: 35576575

Group type: EXPERIMENTAL
Intervention: OWL-H eHealth platform with teaching kitchen medical group visits (TKMGVs)
Number of subjects: 25
Study: 35576863

Group type: EXPERIMENTAL
Intervention: CNN model-based motion compensation method
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Tracking of the rapid pacing catheter tip with CC
Number of subjects: 1690
Study: 35576960

Group type: EXPERIMENTAL
Intervention: Navitoclax plus ruxolitinib (navitoclax orally administered at 50 mg per day, escalated weekly to a maximum of 300 mg per day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Navitoclax plus ruxolitinib
Number of subjects: 34
Study: 35577100

Group type: EXPERIMENTAL
Intervention: FFA clearance in people with obesity during hyperinsulinemic-euglycemic clamp procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FFA kinetics during basal conditions
Number of subjects: 60
Study: 35577503

Group type: EXPERIMENTAL
Intervention: Emactuzumab (1000 mg) + Atezolizumab (1200 mg)
Number of subjects: 221
Study: 35577536

Group type: EXPERIMENTAL
Intervention: Guided Step-by-Step intervention
Number of subjects: 680

Group type: COMPARATOR
Intervention: Enhanced care as usual (ECAU)
Number of subjects: 680
Study: 35577814

Group type: EXPERIMENTAL
Intervention: Flexible insulin therapy (FIT) with heart rate sensors and automated closed insulin loop
Number of subjects: 0
Study: 35578270

Group type: EXPERIMENTAL
Intervention: Aggressive interventions (hospital death, anti-cancer treatment, more than 14 days in hospital, more than one hospital admission, more than one emergency room visit, at least one ICU admission)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Aggressive interventions
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Intervening early in the sub-group of patients with history of hospitalization
Number of subjects: 345
Study: 35578398

Group type: EXPERIMENTAL
Intervention: Recent significant life-events (defined as changes in schooling/employment, residence, partnerships, sickness, incarceration status, family strife or death, and birth/pregnancy, self-reported alcohol use, being a parent, and HIV-status disclosure)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Recent significant life-events
Number of subjects: 995
Study: 35578615

Group type: EXPERIMENTAL
Intervention: Granola with low beta-glucan (0.8 g)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Granola with medium beta-glucan (3.2 g)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Granola with high beta-glucan (6.6 g)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Granola with beta-glucan (various amounts)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (200 ml low-fat milk)
Number of subjects: 14
Study: 35578807

Group type: EXPERIMENTAL
Intervention: Chronic metformin treatment with aerobic training (EXER+MET)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Aerobic training without metformin (EXER)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Chronic metformin treatment
Number of subjects: 63
Study: 35579010

Group type: EXPERIMENTAL
Intervention: Early revascularization
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Noninvasive management
Number of subjects: 1000
Study: 35579040

Group type: EXPERIMENTAL
Intervention: T2-high severe asthma (n=17)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: T2-intermediate severe asthma (n=21)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: T2-low severe asthma (n=20)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy controls (n=28)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All asthma groups
Number of subjects: 86
Study: 35579096

Group type: EXPERIMENTAL
Intervention: Constitutionally thin individuals (CT) during overfeeding
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal-weight individuals (control) during overfeeding
Number of subjects: 63
Study: 35579382

Group type: COMPARATOR
Intervention: Multimodal physiotherapy
Number of subjects: 1339
Study: 35579486

Group type: EXPERIMENTAL
Intervention: Medication iatrogenic assessment using Trivalle score
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: STOPP criteria assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: START criteria assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Assessment of potentially inappropriate medications
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Assessment of benzodiazepine prescriptions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Assessment of anticholinergic prescriptions
Number of subjects: 100
Study: 35579509

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 180
Study: 35579519

Group type: EXPERIMENTAL
Intervention: Emphysema progression (Fleischner grading system)
Number of subjects: 5056

Group type: COMPARATOR
Intervention: Nonprogressive emphysema
Number of subjects: 5056
Study: 35579690

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR)
Number of subjects: 0
Study: 35579731

Group type: EXPERIMENTAL
Intervention: KX2-391 120 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: KX2-391 160 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: KX2-391 140 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: KX2-391
Number of subjects: 24
Study: 35579840

Group type: EXPERIMENTAL
Intervention: Medium Dose (MD) of MVC-COV1901
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High Dose (HD) of MVC-COV1901
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low Dose (LD) of MVC-COV1901
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Three doses of MVC-COV1901
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Booster dose of MVC-COV1901
Number of subjects: 45
Study: 35579862

Group type: EXPERIMENTAL
Intervention: Naxitamab in combination with granulocyte-macrophage colony-stimulating factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naxitamab
Number of subjects: 0
Study: 35579915

Group type: EXPERIMENTAL
Intervention: Sexual assault prevention intervention
Number of subjects: 31
Study: 35579928

Group type: EXPERIMENTAL
Intervention: Virtual environment intervention for CVD prevention education
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 80
Study: 35579931

Group type: EXPERIMENTAL
Intervention: Web-based Parent-Based Intervention (PBI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 35579938

Group type: EXPERIMENTAL
Intervention: Low myocardial ATP levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal ATP levels
Number of subjects: 0
Study: 35580123

Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35580141

Group type: EXPERIMENTAL
Intervention: SCRI-CAR19v2
Number of subjects: 21

Group type: COMPARATOR
Intervention: SCRI-CAR19v1
Number of subjects: 21
Study: 35580160

Group type: EXPERIMENTAL
Intervention: ESE plus lung ultrasound (4-site simplified scan)
Number of subjects: 4392

Group type: COMPARATOR
Intervention: Control subjects (n=103)
Number of subjects: 4392
Study: 35580298

Group type: EXPERIMENTAL
Intervention: ctDNA detected in serum
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ctDNA detected in urine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Agreement between serum ctDNA detection and tumor sequencing results
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Event-free survival (EFS) in patients with ctDNA detected in serum
Number of subjects: 50

Group type: COMPARATOR
Intervention: Event-free survival (EFS) in patients without ctDNA detected in serum
Number of subjects: 50
Study: 35580314

Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 0
Study: 35580913

Group type: EXPERIMENTAL
Intervention: Prereferral rectal artesunate (RAS)
Number of subjects: 2104
Study: 35580970

Group type: EXPERIMENTAL
Intervention: Specialist management in 10 long COVID clinics across the UK
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Patient self-management at home with technology-supported monitoring
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Generalist management in primary care using electronic record data
Number of subjects: 5000
Study: 35581305

Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise (4×4-min intervals at 90-95% of maximal heart rate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 35581464

Group type: EXPERIMENTAL
Intervention: DiamondTemp Ablation (DTA) RF generator
Number of subjects: 60
Study: 35581627

Group type: EXPERIMENTAL
Intervention: 16 mg t-PA with 5 mg DNase administered over 24 h
Number of subjects: 30
Study: 35581637

Group type: EXPERIMENTAL
Intervention: Dynamic FDG-PET (Patlak analysis)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Static FDG-PET
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dynamic FDG-PET (other kinetic models)
Number of subjects: 30
Study: 35582784

Group type: EXPERIMENTAL
Intervention: rTMS (1 Hz over the right dorsolateral prefrontal cortex)
Number of subjects: 38
Study: 35583175

Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for pulmonary tuberculosis detection
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for isoniazid resistance detection
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for fluoroquinolone resistance detection
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for ethionamide resistance detection
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for amikacin resistance detection
Number of subjects: 1228
Study: 35583185

Group type: EXPERIMENTAL
Intervention: 18F-fluorocholine (18FCH) PET/CT
Number of subjects: 107
Study: 35583798

Group type: EXPERIMENTAL
Intervention: Females with ATTRwt amyloidosis
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Males with ATTRwt amyloidosis
Number of subjects: 1386
Study: 35583828

Group type: EXPERIMENTAL
Intervention: CSF_CEA
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CSF_ctDNA
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CSF_CEA combined with CSF_ctDNA
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CSF_ctDNA for LM patients with hydrocephalus
Number of subjects: 54
Study: 35584346

Group type: EXPERIMENTAL
Intervention: Whole-body ER imaging with 16α-[
Number of subjects: 200
Study: 35584349

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 23
Study: 35584850

Group type: EXPERIMENTAL
Intervention: Post-COVID participants (ever-COVID)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Post-COVID participants (ever-hospitalised)
Number of subjects: 85
Study: 35584870

Group type: EXPERIMENTAL
Intervention: Nasal inoculation with maternal respiratory microbiota
Number of subjects: 20